中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (1): 205-206.doi: 10.4103/NRR.NRR-D-23-02017

• 观点:退行性病与再生 • 上一篇    下一篇

阿尔茨海默病的血液生物标志物:临床应用的重要考虑因素

  


  • 出版日期:2025-01-15 发布日期:2025-01-15

Blood biomarkers of Alzheimer’s disease: important considerations for use in clinical practice

Sarah Fullam*, Sean O’Dowd, Antoinette O’Connor   

  1. Department of Neurology, Tallaght University Hospital, Dublin, Ireland (Fullam S, O’Dowd S, O’Connor A)
    Academic Unit of Neurology, Trinity College Dublin, Ireland (O’Dowd S)
  • Online:2025-01-15 Published:2025-01-15
  • Contact: Sarah Fullam, sfullam@tcd.ie.

摘要: https://orcid.org/0000-0002-9657-5823 (Sarah Fullam)

Abstract: Fluid and positron emission tomography (PET) biomarkers that enable the detection of the hallmark proteins of Alzheimer’s disease (AD) (amyloid and tau) have revolutionized our approach to the diagnosis of AD. The evolution of AD diagnostic criteria to include biological characterization (Alzheimer’s Association Working Group, 2023) provides an appropriate framework to reduce levels of clinico-pathologic mismatch and improve in-vivo diagnostic accuracy. As the therapeutic landscape for neurodegenerative disease evolves, it is increasingly incumbent on clinicians to provide timely, and pathologically precise diagnoses for patients. However, the expensive and invasive nature of these tests limits their scalability.